Results 181 to 190 of about 26,639 (274)

Mimic, target, and adapt: Cell membrane‐coated nanoplatforms for precision and immune‐guided cancer treatment

BMEMat, EarlyView.
This Perspective explores the emerging landscape of cell membrane‐coated nanoparticles (CM‐NPs) as intelligent, immune‐compatible platforms for cancer therapy. Highlighting design strategies, translational challenges, and competitive positioning, it outlines how integrating biomimetic targeting with advanced analytical and manufacturing tools could ...
A. K. M. M. Alam, Xiaojun Cai, Malik Ihsan Ullah Khan, Robert Musiol, Quazi T. H. Shubhra   +4 more
wiley   +1 more source

Diagnostic Performance of Prothrombin Time and Activated Partial Thromboplastin Time in Children: A Service Evaluation. [PDF]

Int J Lab Hematol
Gurumurthy G, Lemma M, Reynolds L, Grainger J, Thachil J.   +4 more
europepmc   +1 more source

Advanced nanotherapeutics for combating ocular infections: Rational design, antimicrobial mechanisms, and therapeutic breakthroughs

BMEMat, EarlyView.
Nanomaterials revolutionize ocular infection treatment by enabling targeted drug delivery and enhanced antimicrobial efficacy against resistant pathogens. This review systematically explores their rational design, multimodal mechanisms, and translational potential for next‐generation anti‐infective therapies.
Yujia Liu, Xuetian Wen, Yue Tan, Rui Zeng, Yijuan Zhang, Tong Lin, Lan Gong, Zichao Luo   +7 more
wiley   +1 more source

Inherited Platelet Disorders During Pregnancy and Delivery: Overview of Management Strategies and Emerging Therapeutic Considerations. [PDF]

Hematol Rep
Zibara V, Machin N.
europepmc   +1 more source

Transforming Brain Health With Neurotechnology Convergence (Part II): Intelligent Neurointervention Systems for Neurological Disorders

Brain Health, EarlyView.
ABSTRACT Neurological disorders represent a critical domain within global health, necessitating advanced interventions to address complex pathologies such as tumors, functional disorders, and cerebrovascular diseases. Despite the proven benefits of early intervention, current treatment paradigms face significant challenges: (1) limited precision in ...
Qing Ye, Fei Peng, Chao Pan, Ping Zhang, Xuewei Xie, Zixiao Li, Yingxin Tang, Danyang Chen, Yuanwei Li, Jiawen Wu, Zao Han, Qing Dai, Quansheng Gu, Jizong Zhao, Zhouping Tang   +14 more
wiley   +1 more source

Chiari I Malformation: Review and Update of Current Treatment Options

Clinical Anatomy, EarlyView.
ABSTRACT The pathophysiology of Chiari malformation type I (CM‐I) is complex, involving structural abnormalities at the craniovertebral junction that result in herniation of the cerebellar tonsils through the foramen magnum. In this study, we aim to present and evaluate current treatment options for CM‐I, with a focus on evidence‐based clinical ...
Jordan J. Lo, Shuhei Shiino, Stephen Z. Shapiro, Brianna L. Hines, Noritaka Komune, Carmine Antonio Donofrio, Filippo Badaloni, Antonio Fioravanti, Joseph Lockwood, C. J. Bui, Aaron S. Dumont, R. Shane Tubbs   +11 more
wiley   +1 more source

Congenital Afibrinogenemia With Coexisting Factor V Leiden Mutation Complicated by Budd-Chiari Syndrome: A Case Report. [PDF]

Cureus
Boutari RA, Hsayan FI, Mallah F, Diab M.
europepmc   +1 more source

Actionable Pharmacogenomics and Essential Medicines: An Analysis of WHO and African Lists for Safer and Efficacious Drug Use

Clinical Pharmacology &Therapeutics, EarlyView.
The World Health Organization Model Essential Medicines List and African national essential medicines lists (EMLs) detail drugs intended to be consistently available within national health systems, thereby supporting clinicians and pharmacists in making evidence‐based treatment decisions.
Tinashe A. Mazhindu, Mohamed Nagy, David Twesigomwe, Gaye Agesa, Janine Scholefield, Collen Masimirembwa   +5 more
wiley   +1 more source

A Comprehensive Review of Gene Mutations in Inherited Blood Disorders Among the Saudi Population. [PDF]

Hum Mutat
Younis NS, Alkabsh RM, Nasser Alqahtani SM, Aljuail H, Alhashim MA, Bokhamsin SA, Albaqshi LJ, Alqadhib SF, Aldandan JA, Alshakhs ZA, Altaweel MH, Mohamed ME.   +11 more
europepmc   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source